Tag: FDA Law ⋅ Page 1

Professor Lietzan named a “Best Lawyer in America” for 2020

Professor Erika Lietzan has again been named a “Best Lawyer in America” in both FDA Law and Biotechnology & Life Sciences. This marks the seventh year in a row for FDA Law and the thirteenth year in a row for Biotechnology Law. The Best Lawyers honor is meant to identify the top 5 percent of practicing attorneys in the United…

Professor Lietzan speaks at The Federalist Society’s COVID-19 & the Law Conference

Professor Erika Lietzan spoke at The Federalist Society’s COVID-19 & the Law Conference, contributing to the panel Regulation or “Don’t Let a Good Crisis Go to Waste.” She focused on decisions by regulators to de-regulate during the crisis — decisions to exercise enforcement discretion, to waive paperwork requirements, and to remove otherwise applicable restrictions — including decisions made by FDA…

Professor Lietzan’s FDA Expertise Sought by National & International Media

Professor Erika Lietzan researches, writes, and teaches primarily in the areas of food and drug regulation, intellectual property, and administrative law. Some of her recent scholarship has focused on the nature and purpose of the new drug approval system, federal regulation of fecal microbiota transplantation, federal regulation of products derived from cannabis, the political economy of the Hatch-Waxman (generic drug)…

Professor Lietzan continues to write about the FDA regulation of CBD products

In a recent editorial for Drug Discovery Today, “A special exception for CBD in foods and supplements?”, Professor Erika Lietzan and co-author Patricia J. Zettler,  write about the emerging cannabidiol (CBD) market. They explain that most foods and dietary supplements containing CBD – even CBD from hemp — violate FDA’s “drug exclusion rules.” FDA has not been taking enforcement action,…

Professor Lietzan Named a “Best Lawyer in America”

Professor Erika Lietzan has again been named a “Best Lawyer in America”  in both FDA Law and Biotechnology & Life Sciences. This marks the sixth year in a row for FDA Law and the twelfth year in a row for Biotechnology Law. The Best Lawyers honor is meant to identify the top 5 percent of practicing attorneys in the United…

Professor Lietzan Receives ‘Best Lawyer’ honors

Professor Erika Lietzan has been named a “Best Lawyer in America”  in FDA Law and in Biotechnology and Life Sciences Law.  This marks the sixth year in a row for FDA law and the twelfth year in a row for biotechnology law.  The Best Lawyers honor is meant to identify the top 5 percent of practicing attorneys in the United…

Professor Lietzan Speaks on Panel at Supreme Court IP Review

Professor Erika Lietzan recently served as a panelist at the Supreme Court IP Review held at the Chicago-Kent College of Law. She discussed Sandoz, Inc. v. Amgen. Inc., a case decided by the Supreme Court last June. In October 2014, Amgen, a biopharmaceutical company which manufactures Neupogen, an innovative bone marrow stimulant, sued Sandoz, a biopharmaceutical company which manufactures Zarxio,…

Professor Lietzan Named Best Lawyer in FDA Law and Biotechnology Law

Professor Lietzan has again been named a “Best Lawyer in America” in both FDA Law and Biotechnology Law. This marks the fifth year in a row for FDA Law and the eleventh year in a row for Biotechnology Law. The Best Lawyers honor is meant to identify the top 5 percent of practicing attorneys in the United States, and it…

Professor Lietzan Discusses Executive Order’s Possible Impact on Food and Drug Administration

Professor Erika Lietzan was quoted at length today in an article published by the Regulatory Affairs Professional Society (RAPS) about the impact of President Trump’s January 30 “two-for-one” executive order on the U.S. Food and Drug Administration (FDA). The executive order provides that whenever an agency promulgates a new regulation, it must identify at least two existing regulations to be…